Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 5Phase 1/2 5Phase NA 3Phase 3 1

Status

Completed 222Terminated 105Recruiting 87Unknown 43Active not recruiting 42Withdrawn 30Not yet recruiting 8Suspended 5Enrolling by invitation 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 14Other hematologic neoplasm 7Lymphoid 6Dermatologic 5Tumor-Agnostic 4Thoracic 4CNS 4Other solid neoplasm 3Myeloid 3Genitourinary 3Breast 3Sarcoma 2Plasma cell 2Gynecologic 2NET 1Endocrine 1

Conditions

Melanoma 3Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Hypotension 1Carcinoma, Renal Cell 1Carcinoma, Basal Cell 1Brain Neoplasms 1Basal Cell Nevus Syndrome 1

Interventions

pembrolizumab 2propranolol CR 1imisopasem manganese 1gusacitinib 1Propranolol 1Drug Therapy 1CA-4948 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Suspended × Dermatologic × Clear all
NCT03384836 2025-07-02

Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery

Roswell Park Cancer Institute

Phase 1/2 Suspended
47 enrolled
Dermatologic

Melanoma

NCT05669352 2025-04-04

A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases

University of Florida

Phase 1/2 Suspended
29 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

NCT05138458 2023-11-13

IMAGINE

Myeloid Therapeutics

Phase 1/2 Suspended
40 enrolled
DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT03208296 2023-02-06

Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)

Ascend Biopharmaceuticals Ltd

Phase 1/2 Suspended
24 enrolled
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT00033956 2005-06-24

Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2

MetaPhore Pharmaceuticals

Phase 1/2 Suspended
48 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Hypotension, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡